Allergan plc (NYSE:AGN) Shares Purchased by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. boosted its stake in Allergan plc (NYSE:AGN) by 4.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 108,366 shares of the company’s stock after acquiring an additional 4,280 shares during the period. Tocqueville Asset Management L.P.’s holdings in Allergan were worth $18,144,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of AGN. Dimensional Fund Advisors LP lifted its stake in Allergan by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,606,982 shares of the company’s stock worth $214,787,000 after acquiring an additional 13,100 shares during the period. Geode Capital Management LLC raised its holdings in Allergan by 6.6% in the fourth quarter. Geode Capital Management LLC now owns 4,000,839 shares of the company’s stock worth $533,767,000 after purchasing an additional 247,743 shares in the last quarter. Two Sigma Advisers LP bought a new position in Allergan in the fourth quarter worth $708,000. Mercer Global Advisors Inc. ADV bought a new position in Allergan in the first quarter worth $2,061,000. Finally, Virtu Financial LLC bought a new position in Allergan in the first quarter worth $1,851,000. Hedge funds and other institutional investors own 79.95% of the company’s stock.

AGN has been the subject of a number of research reports. SunTrust Banks increased their price objective on Allergan to $185.00 and gave the stock a “buy” rating in a report on Wednesday, July 3rd. Raymond James downgraded Allergan from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 25th. Leerink Swann downgraded Allergan from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $217.00 to $188.00 in a report on Thursday, July 18th. UBS Group decreased their price objective on Allergan from $173.00 to $172.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Finally, Sanford C. Bernstein downgraded Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price objective for the company. in a report on Tuesday, July 16th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have issued a buy rating to the company’s stock. Allergan has an average rating of “Hold” and a consensus target price of $180.00.

Shares of NYSE:AGN traded down $1.18 on Monday, hitting $158.66. 1,632,541 shares of the company traded hands, compared to its average volume of 5,011,654. Allergan plc has a 52 week low of $114.27 and a 52 week high of $197.00. The company has a current ratio of 1.69, a quick ratio of 0.60 and a debt-to-equity ratio of 0.39. The business has a 50 day moving average price of $161.32. The company has a market capitalization of $52.07 billion, a P/E ratio of 9.51, a PEG ratio of 1.52 and a beta of 1.63.

Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The firm had revenue of $4.09 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period last year, the company earned $4.42 earnings per share. The company’s revenue was down .8% on a year-over-year basis. On average, equities analysts anticipate that Allergan plc will post 16.64 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be issued a $0.74 dividend. The ex-dividend date is Monday, August 12th. This represents a $2.96 annualized dividend and a yield of 1.87%. Allergan’s payout ratio is 17.74%.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

See Also: Buyback For Investors Defined

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit